Jadwiga Paszkowska

Dr. Jadwiga Paszkowska

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Daniel ZakowieckiDaniel Zakowiecki
Daniel Zakowiecki
MFMaja Frankiewicz
Maja Frankiewicz
Tobias HessTobias Hess
Tobias Hess
Krzysztof CalKrzysztof Cal
Krzysztof Cal
MGMaciej Gajda
Maciej Gajda
DHDorota Haznar-Garbacz
Dorota Haznar-Garbacz
Novel calcium phosphate-based starter pellets were used to develop a biphasic-release multiple-unit pellet system (MUPS) with diclofenac sodium as a model drug in the form of hard gelatin capsules. For comparative purposes, corresponding formulations based on the inert cores made of microcrystalline cellulose, sucrose and isomalt were prepared. The developed system consisted of two types of drug-layered pellets attaining different release patterns: delayed-release (enteric-coated) and extended-release. Dissolution characteristics were examined using both compendial and biorelevant methods, which reflected fed and fasting conditions. The results were collated with an equivalent commercial product but prepared with the direct pelletization technique.

1 December 2020 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Open access
Daniel ZakowieckiDaniel Zakowiecki
Daniel Zakowiecki
MSMaja Szczepanska
Maja Szczepanska
THTobias Hess
Tobias Hess
KCKrzysztof Cal
Krzysztof Cal
BMBarbara Mikolaszek
Barbara Mikolaszek
GGGrzegorz Garbacz
Grzegorz Garbacz

31 July 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MSMarcela Staniszewska
Marcela Staniszewska
MRMichał Romański
Michał Romański
SPSebastian Polak
Sebastian Polak
GGGrzegorz Garbacz
Grzegorz Garbacz
JDJustyna Dobosz
Justyna Dobosz
Dorota DanielakDorota Danielak
Dorota Danielak
Gastric mechanical stress often impacts drug dissolution from solid oral dosage forms, but in vitro experiments cannot recreate the substantial variability of gastric motility in a reasonable time. This study, for the first time, combines a novel dissolution apparatus with the design of experiments (DoE) and machine learning (ML) to overcome this obstacle. The workflow involves the testing of soft gelatin capsules in a set of fasted-state biorelevant dissolution experiments created with DoE. The dissolution results are used by an ML algorithm to build the classification model of the capsule’s opening in response to intragastric stress (IS) within the physiological space of timing and magnitude. Next, a random forest algorithm is used to model the further drug dissolution. The predictive power of the two ML models is verified with independent dissolution tests, and they outperform a polynomial-based DoE model. Moreover, the developed tool reasonably simulates over 50 dissolution profiles under varying IS conditions. Hence, we prove that our method can be utilized for the simulation of dissolution profiles related to the multiplicity of individual gastric motility patterns. In perspective, the developed workflow can improve virtual bioequivalence trials and the patient-centric development of immediate-release oral dosage forms.

2 April 2023 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Open access
Dorota DanielakDorota Danielak
Dorota Danielak
JPJadwiga Paszkowska
Jadwiga Paszkowska
MSMarcela Staniszewska
Marcela Staniszewska
GGGrzegorz Garbacz
Grzegorz Garbacz
ATAnna Terlecka
Anna Terlecka
MRMichał Romański
Michał Romański

23 November 2023 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MRMichał Romański
Michał Romański
JGJoanna Giebultowicz
Joanna Giebultowicz
EGElżbieta Gniazdowska
Elżbieta Gniazdowska
RPRoman Piotrowski
Roman Piotrowski
AŻAnna Żuk
Anna Żuk
Dorota DanielakDorota Danielak
Dorota Danielak

28 May 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
EJEwelina Juszczyk
Ewelina Juszczyk
KKKamil Kisło
Kamil Kisło
PŻPaweł Żero
Paweł Żero
ETEwa Tratkiewicz
Ewa Tratkiewicz
MWMaciej Wieczorek
Maciej Wieczorek
Dorota DanielakDorota Danielak
Dorota Danielak
Sustained-release (SR) formulations may appear advantageous in first-in-human (FIH) study of innovative medicines. The newly developed SR matrix tablets require prolonged maintenance of API concentration in plasma and should be reliably assessed for the risk of uncontrolled release of the drug. In the present study, we describe the development of a robust SR matrix tablet with a novel G-protein-coupled receptor 40 (GPR40) agonist for first-in-human studies and introduce a general workflow for the successful development of SR formulations for innovative APIs. The hydrophilic matrix tablets containing the labeled API dose of 5, 30, or 120 mg were evaluated with several methods: standard USP II dissolution, bio-predictive dissolution tests, and the texture and matrix formation analysis. The standard dissolution tests allowed preselection of the prototypes with the targeted dissolution rate, while the subsequent studies in physiologically relevant conditions revealed unwanted and potentially harmful effects, such as dose dumping under an increased mechanical agitation. The developed formulations were exceptionally robust toward the mechanical and physicochemical conditions of the bio-predictive tests and assured a comparable drug delivery rate regardless of the prandial state and dose labeled. In conclusion, the introduced development strategy, when implemented into the development cycle of SR formulations with innovative APIs, may allow not only to reduce the risk of formulation-related failure of phase I clinical trial but also effectively and timely provide safe and reliable medicines for patients in the trial and their further therapy.